Logo
x

Search

Subscribe Now

Johnson & Johnson

Johnson & Johnson’s Darzalex Faspro Quadruplet Combination Gains the US FDA’s Approval to Treat Multiple Myeloma (MM)

Johnson & Johnson’s Darzalex Faspro Quadruplet Combination Gains the US FDA’s Approval to Treat Multiple Myeloma (MM)

  • July 31, 2024
Johnson & Johnson Reports sNDA Submission of Spravato to the US FDA for Treatment-Resistant Depression

Johnson & Johnson Reports sNDA Submission of Spravato to the US FDA for Treatment-Resistant Depression

  • July 22, 2024
Johnson & Johnson’s Sirturo Gains the US FDA & EC’s Approval to Treat Pulmonary Tuberculosis

Johnson & Johnson’s Sirturo Gains the US FDA & EC’s Approval to Treat Pulmonary Tuberculosis

  • July 3, 2024
Johnson & Johnson Reports sBLA Submission of Tremfya to the US FDA for Treating Crohn’s Disease

Johnson & Johnson Reports sBLA Submission of Tremfya to the US FDA for Treating Crohn’s Disease

  • June 21, 2024
Johnson & Johnson Reports the BLA Submission of SC Amivantamab to the US FDA for Treating Non-Small Cell Lung Cancer

Johnson & Johnson Reports the BLA Submission of SC Amivantamab to the US FDA for Treating Non-Small Cell Lung Cancer

  • June 18, 2024
Johnson & Johnson Reports P-III (MDD3001) Study Data of Seltorexant for Treating Major Depressive Disorder

Johnson & Johnson Reports P-III (MDD3001) Study Data of Seltorexant for Treating Major Depressive Disorder

  • May 30, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.